TXA Central is a resource for health professionals caring for patients with acute severe bleeding
Intravenous (IV) Tranexamic Acid (TXA) reduces death from bleeding in patients with postpartum haemorrhage (PPH) and traumatic injuries.
However, patients must be treated urgently – most haemorrhage deaths occur within hours of bleeding onset, and treatment delay reduces the survival benefit from TXA. With every 15 minute delay, 10% of the survival benefit is lost.
One of the main obstacles to reducing treatment delay is the need for an IV injection.
In trauma patients, securing IV access at the injury scene can be difficult, particularly in trapped patients.
In countries with limited pre-hospital care, most trauma patients arrive at hospital too late to benefit from TXA.
The WOMAN trial showed that IV administration of TXA reduces PPH deaths by one-third, TXA was incorporated into the World Health Organisation guidelines.
To ensure equitable access to this life-saving treatment, finding other routes to give TXA became a WHO priority.
Because many women die soon after PPH onset and the life-saving effect of TXA decreases by 10% with every 15-minute delay, finding alternatives to IV administration offers women effective emergency care wherever they give birth.
Click HERE to watch a PPH stakeholder webinar discussing alternative routes for the administration of tranexamic acid (TXA) in post-partum haemorrhage (PPH).
WOMANPharmaco-TXA Trial Protocol
This is a Phase 2 trial assessing the pharmacokinetics and pharmacodynamics of tranexamic acid administered by intravenous, intramuscular and oral liquid routes in women giving birth by caesarean section with at least one risk factor for PPH
Stakeholder webinar: Alternative routes for the administration of tranexamic acid (TXA) in post-partum haemorrhage (PPH)